

# The feasibility and safety of the use of automated oxygen in babies admitted to the neonatal intensive care unit

<b>Submission date</b> 18/10/2021	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 28/10/2021	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 09/12/2022	<b>Condition category</b> Respiratory	<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

### Background and study aims

As both excess and shortage of oxygen can be harmful to a baby born prematurely (before the usual end of pregnancy) we investigate whether it is possible to use automated oxygen control and if this is better than manual control of oxygen by a nurse or other healthcare provider.

### Who can participate?

Preterm babies admitted to one of the participating Neonatal Intensive Care Units (NICU), requiring respiratory support and extra oxygen can participate.

### What does the study involve?

The study involves a control period of 8 hours on manual control of oxygen, followed by a study period where automated oxygen control is turned on but still supervised by the nurse that takes care of the baby. After this period another control period of 8 hours on manual control follows. During the study period, the baby's oxygen levels are continuously monitored.

### What are the possible benefits and risks of participating?

Due to the short study period and the continuous monitoring we expect no benefits or harm for the baby.

### Where is the study run from?

Erasmus MC/Sophia's Children's Hospital (The Netherlands)

### When is the study starting and how long is it expected to run for?

August 2016 to January 2020

### Who is funding the study?

Investigator initiated and funded

### Who is the main contact?

K.P. Dijkman, [k.dijkman@mmc.nl](mailto:k.dijkman@mmc.nl)

# Contact information

## Type(s)

Scientific

## Contact name

Mr Koen Dijkman

## ORCID ID

<http://orcid.org/0000-0003-0765-929X>

## Contact details

De Run 4600

Veldhoven

Netherlands

5504DB

+31 40 8889350

k.dijkman@mmc.nl

# Additional identifiers

## EudraCT/CTIS number

Nil known

## IRAS number

## ClinicalTrials.gov number

Nil known

## Secondary identifying numbers

NL51887.000.16

# Study information

## Scientific Title

Safety and feasibility of Predictive Intelligent Control of Oxygenation (PRICO) on the Neonatal Intensive Care Unit (NICU)

## Study objectives

Fully automated FiO2 control conducted by this algorithm will keep SpO2 within a predefined target range more time and with less deviation than during routine standard clinical care.

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Approved 02/08/2016, CCMO: Central Committee on Research Involving Human Subjects (Mailbox 16302, 2500BH The Hague, The Netherlands; +31 70 340 67 00; [ccmo@ccmo.nl](mailto:ccmo@ccmo.nl)), ref: NL51887.000.16

**Study design**

Multicenter interventional crossover feasibility study

**Primary study design**

Interventional

**Secondary study design**

Non randomised study

**Study setting(s)**

Hospital

**Study type(s)**

Treatment

**Participant information sheet**

See additional files (in Dutch)

**Health condition(s) or problem(s) studied**

Preterm newborns with oxygen requirement

**Interventions**

Newborns on respiratory support requiring oxygen will be subjected to an 8 hour study period of automated control of oxygen with the PRICO algorithm that is used to control O<sub>2</sub> on the Fabian HFO ventilator (Acutronic Meical GmbH, Hirzel, Switzerland). The 8 hour study period is flanked by two 8 hour periods of routine manual control of oxygen which is the current stand of care.

**Intervention Type**

Device

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Respiratory support

**Primary outcome measure**

Time spent within the SpO<sub>2</sub> target range measured using a pulse oximeter and logged at 1/s interval both during the study and during the control periods

**Secondary outcome measures**

Time spent below target range, time spent above target range, average FiO<sub>2</sub> and SpO<sub>2</sub> measured using a pulse oximeter and logged at 1/s interval both during the study and during the control periods

**Overall study start date**

02/08/2016

**Completion date**

01/01/2020

# Eligibility

## Key inclusion criteria

Newborns receiving respiratory support and a FiO<sub>2</sub> more than 21% while having an SpO<sub>2</sub> of 95% or less and no plans to change ventilation mode during the next 24 hours

## Participant type(s)

Patient

## Age group

Neonate

## Sex

Both

## Target number of participants

25

## Total final enrolment

32

## Key exclusion criteria

1. Major congenital or chromosomal defects
2. Plans to transfer the patient out within 24 hours
3. Plans to change ventilation mode within 24 hours

## Date of first enrolment

27/09/2016

## Date of final enrolment

27/12/2019

# Locations

## Countries of recruitment

Netherlands

## Study participating centre

Erasmus MC/Sophia's Children's Hospital  
Wytemaweg 80  
Rotterdam  
Netherlands  
3015CN

## Study participating centre

**Maxima Medical Center**

De Run 4600  
Veldhoven  
Netherlands  
5504DB

## Sponsor information

**Organisation**

Erasmus MC - Sophia Children's Hospital

**Sponsor details**

Wytemaweg 80  
Rotterdam  
Netherlands  
3015CN  
+31 10 703 6077  
i.reiss@erasmusmc.nl

**Sponsor type**

Hospital/treatment centre

**Website**

<http://www.erasmusmc.nl/sophia/>

**ROR**

<https://ror.org/047afsm11>

## Funder(s)

**Funder type**

Other

**Funder Name**

Investigator initiated and funded

## Results and Publications

**Publication and dissemination plan**

Planned publication in a peer-reviewed Journal

**Intention to publish date**

01/01/2022

## Individual participant data (IPD) sharing plan

The current data sharing plans for this study are unknown and will be available at a later date

## IPD sharing plan summary

Data sharing statement to be made available at a later date

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Participant information sheet</a>	Primary data		28/10/2021	No	Yes
<a href="#">Protocol file</a>		01/10/2015	28/10/2021	No	No
<a href="#">Results article</a>		08/12/2022	09/12/2022	Yes	No